ROFACT CAPSULE

Valsts: Kanāda

Valoda: angļu

Klimata pārmaiņas: Health Canada

Aktīvā sastāvdaļa:

RIFAMPIN

Pieejams no:

BAUSCH HEALTH, CANADA INC.

ATĶ kods:

J04AB02

SNN (starptautisko nepatentēto nosaukumu):

RIFAMPICIN

Deva:

150MG

Zāļu forma:

CAPSULE

Kompozīcija:

RIFAMPIN 150MG

Ievadīšanas:

ORAL

Vienības iepakojumā:

100

Receptes veids:

Prescription

Ārstniecības joma:

ANTITUBERCULOSIS AGENTS

Produktu pārskats:

Active ingredient group (AIG) number: 0105824002; AHFS:

Autorizācija statuss:

APPROVED

Autorizācija datums:

2019-07-02

Produkta apraksts

PRESCRIBING INFORMATION
INCLUDING PATIENT MEDICATION INFORMATION
Pr
ROFACT
®
Rifampin Capsules, USP
150 mg & 300 mg
Antituberculosis Agent
Date of Preparation:
June 28, 2019
Bausch Health, Canada Inc.
2150 St-Elzear Blvd.West
Laval, Quebec
H7L 4A8
Control #: 228050
ROFACT
®
Prescribing Information
Page 2 of 27
PRESCRIBING INFORMATION
Pr
ROFACT
®
Rifampin Capsules, USP
150 & 300 mg
Antituberculosis Agent
ACTION AND CLINICAL PHARMACOLOGY
Rifampin may be bacteriostatic or bactericidal in action, depending on
the concentration of the
drug attained at the site of infection and the susceptibility of the
infecting organism. Rifampin
usually is rapidly bactericidal against Mycobacterium leprae in vivo.
Rifampin suppresses initiation of chain formation for RNA synthesis in
susceptible bacteria by
inhibiting DNA-depending RNA polymerase. The ß subunit of the enzyme
appears to be the site
of action. Rifampin is most active against susceptible bacteria when
they are undergoing cell
division; however, the drug also has some effect when bacteria are in
the metabolic resting state.
Pharmacokinetics
Absorption
Rifampin is well absorbed from the gastrointestinal tract.
Distribution
Rifampin diffuses well to most body tissues and fluids, including the
cerebrospinal fluid, where
concentrations are increased if the meninges are inflamed;
concentrations in the liver, gallbladder,
bile, and urine are higher than those found in the blood; therapeutic
concentrations are achieved
in the saliva, reaching 20% of serum concentrations; crosses the
placenta, with fetal serum
concentrations at birth found to be approximately 33% of the maternal
serum concentration;
penetrates into aqueous humor; and is distributed into breast milk.
Being lipid-soluble, rifampin
may reach and kill susceptible intracellular, as well as
extracellular, bacteria and Mycobacteria
species.
Volume of Distribution: 1.6 L per kg
Protein binding: high to very high (89%)
Biotransformation: hepatic
ROFACT
®
Prescribing Information
Page 3 of 27
Metabolism
Rifampin is e